Small Cell Lung Cancer Guideline Updates 2020 | videos

Lurbinectedin is being studied in a number of diseases, but in lung cancer it has a more favorable side effect profile compared with topotecan, said Apar Kishor Ganti, MD, University of Nebraska Medical Center.

Small cell lung cancer is an aggressive disease that has had few treatment options before lurbinectedin, said Apar Kishor Ganti, MD, professor of internal medicine, Division of Oncology & Hematology, University of Nebraska Medical Center.

With few treatment options in small cell lung cancer, lurbinectedin was quickly added to the National Comprehensive Cancer Network’s guidelines after the FDA approved it, said Apar Kishor Ganti, MD, of University of Nebraska Medical Center.